Publications Office of the EU
Open House Drug Discount Contracts Announcement of concluded contracts 16.07.2024 - 15.08.2024 - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Open House Drug Discount Contracts Announcement of concluded contracts 16.07.2024 - 15.08.2024 Text automatically translated in your browsing language Automatically translated

Overview
  • Today
    11/07/2025
Status
Submission closed
Type of contract
Supplies
Subject for Renewal
No
Buyer
AOK Bayern - Die Gesundheitskasse
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE212 München, Kreisfreie Stadt
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Procedure details
Tender reference number
24-111
Description

With this announcement, for reasons of transparency, AOK Bayern publishes all contracts concluded within the framework of the open house procedures for drug discount contracts pursuant to § 130a(8) SGB V and § 130a(8)(c) SGB V in the period from 16.07.2024 to 15.08.2024. AOK Bayern intends to conclude non-exclusive rebate agreements with all interested pharmaceutical companies on the active substances mentioned in the respective procedure pursuant to § 130a(8) SGB V or § 130a(8)(c) SGB V. AOK Bayern offers all interested pharmaceutical companies that meet the eligibility requirements listed below the conclusion of identical and non-individually negotiable discount agreements. A contract can be concluded at any time during the term. Contracts may be terminated with a notice period of one month to the end of the month. Upon entry into force of a rebate agreement for medicinal products with the active substance subject to the contract concluded by means of a nationwide or country-specific rebate agreement concluded in an open procedure, the open-house agreements automatically cease to apply for the corresponding term. A contract is concluded with all interested pharmaceutical companies that prove their suitability by means of a completed and signed self-declaration of reliability. Details can be found in the contract notice for the respective open house procedure in the Official Journal of the European Union. Contracts concluded between 16.07.2024 and 15.08.2024: 1. Adalimumab: 2care4 ApS, Esbjerg, Denmark 2. Alitretinoin: EurimPharm Arzneimittel GmbH, Saaldorf-Surheim 3. Bevacizumab: Biosimilar Collaborations Ireland Limited, Dublin, Ireland; Celltrion Healthcare Deutschland GmbH, Bad Homburg vor der Höhe 4. Bimatoprost: Pharma Stulln GmbH, Stulln; TRB Chemedica AG, Feldkirchen 5. Botulinum toxin type A - Botox: PB Pharma GmbH, Meerbusch; EurimPharm Arzneimittel GmbH, Saaldorf-Surheim; AbbVie Deutschland GmbH & Co. KG, Wiesbaden; CC Pharma GmbH, Densborn; Kohlpharma GmbH, Merzig 6. dabigatran etexilate: 1 A Pharma GmbH, Holzkirchen 7. Epinephrine: CC Pharma GmbH, Densborn 8. Erythropoietin zeta: EurimPharm Arzneimittel GmbH, Saaldorf-Surheim 9. Infliximab: 1 4 U Pharma GmbH, Densborn 10. Ozurdex: AbbVie Deutschland GmbH & Co. KG, Wiesbaden 11. Pazopanib: CC Pharma GmbH, Densborn 12. Ribociclib: Allomedic GmbH, Cologne; 1 4 U Pharma GmbH, Densborn; CC Pharma GmbH, Densborn 13. Rituximab: Celltrion Healthcare Deutschland GmbH, Bad Homburg vor der Höhe 14. tacrolimus: B2B Medical GmbH, Rastatt; Medicopharm AG, Nußdorf am Inn 15. Teriparatide: Gedeon Richter Pharma GmbH, Eschborn 16. Trastuzumab: Biosimilar Collaborations Ireland Limited, Dublin, Ireland; Celltrion Healthcare Germany GmbHBad Homburg vor der Höhe Text automatically translated in your browsing language Automatically translated

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
The procurement involves the establishment of a framework agreement
Conditions for opening tenders (date)
Not available
Place of performance
DE Deutschland
Any country
CPV code

33600000 - Pharmaceutical products

Award method
Preis
Estimated value
Not available
Final contracted value
Not available
Award of contract
Not available
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.